In a state that carries one of the highest sickle cell disease burdens in the country, Georgia lawmakers delivered a rare bipartisan win on the final day of their 2026 legislative session — passing a bill that could reshape how the state’s Medicaid program serves tens of thousands of patients living with a condition that has long been undertreated and underresourced.
The Georgia General Assembly passed House Bill 334, known as the Sickle Cell Disease Protection Act, a measure designed to expand treatment access and modernize care for thousands of Georgians living with the condition. The bill, authored by State Rep. Omari Crawford (D-Decatur), would require the Georgia Department of Community Health to conduct annual reviews of emerging sickle cell treatments, ensuring Medicaid coverage keeps pace with medical advancements.
If signed into law by Gov. Brian Kemp, the measure could directly impact nearly 15,000 Georgians living with sickle cell disease — a figure that places the state among the highest-burden populations in the country. “This ensures that Georgia’s healthcare system stays up to date and provides life-altering care,” Crawford said in a statement.
What the Bill Actually Does
The Sickle Cell Disease Protection Act addresses a gap that advocates have pointed to for years: the lag between the approval of new treatments and the point at which state Medicaid programs actually cover them. Medical advances in sickle cell care have accelerated in the past decade, with new disease-modifying therapies now available that were not accessible to most Medicaid recipients even years after receiving federal approval.
House Bill 334 is designed to address gaps in care caused by inaction and inattentiveness by medical professionals. “House Bill 334 would allow input from warriors, experts, medical staff and service people to discuss what better treatments may be possible as medications and treatments evolve,” Crawford said. “We want to be able to better collect data, and if we can better collect data, then we can better address this awful disease.”
The annual review requirement creates an institutional obligation — one that is currently absent from Georgia’s Medicaid framework — to keep the state’s coverage standards in step with what medicine can actually offer. It also mandates public input as part of that review process, giving patients, caregivers, and clinicians a formal voice in coverage decisions rather than leaving those determinations entirely to administrative discretion.
The Sickle Cell Foundation of Georgia gathered at the Georgia state Capitol weeks before the bill’s passage to advocate for the legislation. Foundation CEO Dr. Tabatha McGee said it is important for lawmakers to hear personal accounts from people living with the disease. “We know that their stories are more frank, their stories are real and their stories are tangible,” McGee said, “because it’s their life that they live day to day.”
A Disease That Has Been Historically Underfunded
Sickle cell disease is not a new condition. It has affected American families for generations, and the science behind it has been understood for decades. Yet by nearly every measurable standard, the disease has received less research investment, less pharmaceutical attention, and less clinical infrastructure than comparable conditions.
Sickle cell disease affects about 100,000 people in the United States. More than 90% are non-Hispanic Black or African American, and an estimated 3% to 9% are Hispanic or Latino. The estimated life expectancy of those with sickle cell disease in the United States is more than 20 years shorter than the average expected. Many people with sickle cell disease do not receive the recommended healthcare screenings and treatments.
Sickle cell disease can cause substantial, long-term, and costly health problems, including infections, stroke, and kidney failure, many of which can reduce life expectancy. As an orphan disease — one that affects fewer than 200,000 persons nationwide — it does not receive the research funding and pharmaceutical investment directed to other orphan diseases. Cystic fibrosis, for example, affects fewer than half the number of persons but receives 3.5 times the funding from the National Institutes of Health and 440 times the funding from national foundations.
That funding disparity has real consequences in clinical settings. According to a study by the American Society of Hematology, only one in three sickle cell patients experiencing related pain received appropriate medication within the first hour after seeking care. Patients and caregivers describe a consistent pattern of having their pain dismissed or undertreated — often attributed to providers who are unfamiliar with the disease or skeptical of patient-reported symptoms.
The new Georgia legislation does not solve those systemic problems directly. But it does create an annual accountability mechanism — a formal, public process that requires the state to examine whether its Medicaid coverage is keeping pace and to answer for it on the record.
Georgia’s Position in the National Picture
Georgia has the fourth highest burden of sickle cell disease among U.S. states. The concentration of patients in the state reflects both historical demographics and the broader absence of comprehensive sickle cell infrastructure across the American South — a region where the disease is most prevalent but where specialized treatment centers have historically been least accessible.
The legislation also builds on recent efforts to raise awareness, including Gov. Brian Kemp’s 2025 proclamation recognizing June 19 as Sickle Cell Awareness Day in Georgia. If signed, Georgia would join a growing number of states taking steps to modernize sickle cell care and address long-standing disparities.
That broader state-level momentum matters. Federal funding for sickle cell programs exists but has historically been inconsistent, and the organizations most embedded in affected communities have frequently struggled to access it. Georgia’s law, if enacted, creates a structural mechanism that operates independently of federal funding cycles — one that places the burden of review and accountability on the state itself rather than on patient advocates pushing from the outside.
What Comes Next
The bill now awaits Gov. Kemp’s signature or veto. Kemp, who has previously expressed support for sickle cell awareness through official proclamations, has not publicly indicated his position on HB 334. Advocates remain cautiously optimistic given the bill’s passage with bipartisan support in both chambers on the final day of session.
For patients like those who walked into the Georgia Capitol in March to share their stories with lawmakers, the stakes are not abstract. Sickle cell disease imposes severe pain episodes, hospitalizations, and long-term organ damage on people who are disproportionately low-income and who depend on Medicaid as their primary source of care. When coverage lags behind treatment advances, the gap is measured in suffering that is both preventable and well-documented.
If Georgia’s governor signs the act into law, the state will have established one of the more concrete legislative commitments to Medicaid coverage parity for sickle cell patients that any state has made in recent years. The annual review process, paired with required public input and public reporting, creates exactly the kind of structural accountability that advocates have argued is necessary to close the gap between what medicine can offer and what patients are actually receiving.
Disclaimer: This article is intended for informational purposes only and does not constitute medical or legal advice. Readers with questions about sickle cell disease treatment or Medicaid coverage should consult a qualified healthcare provider or benefits counselor.
